OGN
Organon & Co.
$13.75
-0.07% 2026-10-19
Health CareS&P 600
OGNSPY
1W
-0.1%
1M
+0.5%
3M
+2.1%
6M
+48.9%
YTD
+92.8%
1Y
+49.4%
Grades vs sector
Momentum97th pct in sectorA+
Momentum
97th pct in sector
12-1 return: +104.6%
Percentile within its GICS sector across the S&P 1500.
Percentile within its GICS sector across the S&P 1500.
Growth7th pct in sectorF
Growth
7th pct in sector
Revenue growth (YoY): -2.3%
Percentile within its GICS sector across the S&P 1500.
Percentile within its GICS sector across the S&P 1500.
Value97th pct in sectorA+
Value
97th pct in sector
Forward E/P: 26.3% · EBITDA/EV: 14.2%
Percentile within its GICS sector across the S&P 1500.
Percentile within its GICS sector across the S&P 1500.
Profitability58th pct in sectorB-
Profitability
58th pct in sector
Profit margin: +3.4% · Return on equity: +24.0%
Percentile within its GICS sector across the S&P 1500.
Percentile within its GICS sector across the S&P 1500.
Revisionsno data–
Revisions
no data
EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.
30-day change in analysts' current-year EPS estimate; graded across covered stocks.
Our models
Held by 1 of 3 live models: Momentum Blend.
Momentum Blend
5.4% of the book · Leaders sleeve
HeldMomentum Top 15not ranked (outside this model's universe or screens)
Quality Growthnot ranked (outside this model's universe or screens)
Key stats
Market cap$3.6B
P/E (trailing)17.6
P/E (forward)3.8
52-week range5.69 – 13.83
Revenue growth (YoY, latest qtr)-2.3%
Dividend yield0.58%
Analyst consensusHold (4)
Mean price target$11.25 (-18%)
Valuation & fundamentals
Bottom line
Leans expensive
Model read-out from the numbers below, not advice. Score -2 (DCF counts double).
▼DCF (base case)below the price by 163%
▲Forward P/E vs sector3.8x vs median 17.6x
•Piotroski F-score5/9
▼Analyst target-18% (4 analysts)
Discounted cash flow
Bear
$-15
-207%
growth -6% · disc. 13.0% · term. 2.0%
Base
$-9
-163%
growth -1% · disc. 12.0% · term. 2.5%
Bull
$-2
-112%
growth 2% · disc. 11.0% · term. 3.0%
A DCF starts from trailing free cash flow, so it can overstate value if the last 12 months were unusually strong (or weak). Use the bear case or edit the starting cash flow if so.
Reverse DCFfor context, not a signal
A normal DCF guesses future cash flows and works out a price. A reverse DCF runs it backwards: it starts from today's price and asks how fast free cash flow would have to grow to justify it. It tells you what the market is assuming, not whether the stock is cheap or expensive, and it is not a buy or sell signal. Glossary
Today's price assumes free cash flow grows about 11% a year for 10 years.
Implied
+11%/yr
FCF, last 3 yrs
-7%/yr
FCF, last 5 yrs
n/a
Revenue, last 3 yrs
+0%/yr
Revenue, last 5 yrs
-1%/yr
Same inputs as the DCF above: trailing free cash flow 0.6B, 12.0% discount rate, 2.5% growth after year 10, net debt and today's share count. Actual growth rates are compound annual rates from SEC annual filings through FY2025; "n/a" means too little history or a negative starting year.
Edit assumptions · recalculates instantly
Your value per share–
Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 1.54 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.
Multiples vs Health Care
P/E (trailing)
cheaper
sector median 29.9× · 18th pct
17.6×cheaper
Forward P/E
cheaper
sector median 17.6× · 1st pct
3.8×cheaper
EV / EBITDA
sector median 15.8×
–Price / sales
cheaper
sector median 3.1× · 11th pct
0.6×cheaper
Price / book
pricier
sector median 3.5× · 53rd pct
3.6×pricier
FCF yield
cheaper
sector median 4.1% · 98th pct
15.7%cheaper
Forward EPS $3.62 vs trailing $0.78 (+363% expected growth). Forward P/E uses analysts' next-12-month estimate.
Quality & financial health
Gross margin
52.7%
Operating margin
–
FCF margin
9.3%
Net margin
3.4%
Return on equity
20.8%
Return on invested capital
–
Net debt / EBITDA
–
Current ratio
2.0×
Interest cover
–
Cash conversion (OCF/NI)
3.5×
Piotroski F-score 5/9 · last two fiscal years
✓ Positive net income✓ Positive operating cash flow✗ Return on assets improved✓ Cash flow above net income✓ Long-term debt / assets fell✓ Current ratio improved✗ No share dilution✗ Gross margin improved✗ Asset turnover improved
Analysts
Mean target
$11
-18%
Analysts
4
Hold
Range
$8–$14
low – high
● price · ◆ mean target
Annual history
| FY | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $6.2B | $187.0M | $538.0M |
| 2024 | $6.4B | $864.0M | $764.0M |
| 2023 | $6.3B | $1.0B | $548.0M |
| 2022 | $6.2B | $917.0M | $662.0M |
| 2021 | $6.3B | $1.4B | – |
| 2020 | $6.5B | $2.2B | – |
From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR +0.2%.
Earnings
Next report: 2026-11-09 · before open · EPS est 0.88
EstimateActual (beat)Actual (miss)
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-07-31 | 1.07 | 0.85 | -20.6% |
| 2026-04-30 | 0.85 | 0.71 | -16.8% |
| 2026-02-12 | 0.73 | 0.63 | -13.3% |
| 2025-11-10 | 0.93 | 1.01 | +8.5% |
| 2025-08-05 | 0.94 | 1.00 | +6.4% |
| 2025-05-01 | 0.89 | 1.02 | +14.2% |
| 2025-02-13 | 0.87 | 0.90 | +4.0% |
| 2024-10-31 | 0.90 | 0.87 | -3.7% |
Quarterly revenue
| Quarter | Revenue | YoY |
|---|---|---|
| 2026-06-30 | $1.6B | -2.3% |
| 2026-03-31 | $1.5B | – |
| 2025-12-31 | $1.5B | – |
| 2025-09-30 | $1.6B | – |
| 2025-06-30 | $1.6B | – |
Analyst actions
BNP Paribas
PT $14
2026-04-29 · down
Outperform → NeutralPT $14
Piper Sandler
PT $14
2026-04-28 · up
Underweight → NeutralPT $14
Barclays
PT $8
2026-02-24 · main
Underweight → UnderweightPT $8
Barclays
PT $8
2025-12-09 · init
→ UnderweightPT $8
JP Morgan
PT $12
2025-11-11 · main
Underweight → UnderweightPT $12
Morgan Stanley
PT $9
2025-11-11 · main
Equal-Weight → Equal-WeightPT $9
Recent dividends
2026-08-14: $0.020 · 2026-05-11: $0.020 · 2026-02-23: $0.020 · 2025-11-20: $0.020 · 2025-08-15: $0.020 · 2025-05-12: $0.020 · 2025-02-24: $0.280 · 2024-11-12: $0.280
Insider trades
Drinane Juliana Papa
$200.3K
Head of Mfg & Supply · 2026-08-05
SELL$200.3K
None
–
None · None
SELL–
News
Organon to Report Third Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing
Business Wire · 22h ago
Organon Says 6-Year Miudella Data Supports FDA Application for Extended Use
MT Newswires · Oct 16
Organon Announces Positive Interim Phase 3 Study Results for MIUDELLA®, a Hormone-Free, Intrauterine Device (IUD), Through 6 Years of Use to Be Presented at the 2026 Society of Family Planning Annual Meeting
Business Wire · Oct 16
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know
Zacks · Oct 14
Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock
Zacks · Oct 02
Organon to Present New Real-World Analysis of VTAMA® (tapinarof) Cream, 1%, at the 2026 Fall Clinical Dermatology Conference
Business Wire · Oct 01
Organon Says Nduvra Cream Gets Canada Approval for Atopic Dermatitis
MT Newswires · Sep 28
Why Organon (OGN) Is Getting Attention Today
Simply Wall St. · Sep 22
Stats refreshed 2026-10-19 17:47:06 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
coteau
Coteau Systematic StrategiesSystematic equity research and model portfolios.Coteau Systematic Strategies publishes research, model portfolios and tools. It does not manage money or offer investment advice. Model results are hypothetical. Data: Yahoo Finance (delayed), SEC EDGAR.